Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for NTLA

Stock Name	Intellia Therapeutics Inc
Ticker	NTLA(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US45826J1051
LEI	5493002T5BCPE5DZC723

Show aggregate NTLA holdings

News associated with NTLA

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus: Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach. - 2025-09-02 10:03:00
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up After Insider Buying Activity: Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shares gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $10.52, but opened at $11.07. Intellia Therapeutics shares last traded at $11.34, with a volume of 1,615,773 shares trading hands. Specifically, Director William J. Chase purchased 100,000 shares […] - 2025-08-27 02:18:42
Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA): Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 24.1% in the 1st quarter, HoldingsChannel reports. The firm owned 21,458 shares of the company’s stock after buying an additional 4,165 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth […] - 2025-08-15 05:44:58
Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus: Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty. - 2025-08-11 08:43:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by XTX Topco Ltd: XTX Topco Ltd boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 84.2% in the 1st quarter, HoldingsChannel reports. The firm owned 80,897 shares of the company’s stock after purchasing an additional 36,989 shares during the period. XTX Topco Ltd’s holdings in Intellia Therapeutics were worth $575,000 at the end of the […] - 2025-08-07 04:58:54
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus: AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks. - 2025-07-28 09:41:00
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from Analysts: Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating […] - 2025-07-24 05:11:08
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options: Investors considering a purchase of Intellia Therapeutics Inc (Symbol: NTLA) stock, but tentative about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in - 2025-07-21 12:36:47
Alps Advisors Inc. Sells 5,030 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA): Alps Advisors Inc. trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.1% in the 1st quarter, Holdings Channel reports. The firm owned 77,328 shares of the company’s stock after selling 5,030 shares during the quarter. Alps Advisors Inc.’s holdings in Intellia Therapeutics were worth $550,000 at the end of […] - 2025-07-15 06:25:51
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus: Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears. - 2025-07-14 10:06:00
Wealth Enhancement Advisory Services LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA): Wealth Enhancement Advisory Services LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,789 shares of the company’s stock, valued at approximately $98,000. Several other large investors also recently modified […] - 2025-07-11 04:16:51
Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $33.37: Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given […] - 2025-07-02 03:14:50
SG Americas Securities LLC Sells 3,401 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA): SG Americas Securities LLC lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,437 shares of the company’s stock after selling 3,401 shares during the quarter. SG Americas Securities LLC’s […] - 2025-06-27 04:21:01
Rhumbline Advisers Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA): Rhumbline Advisers trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 156,838 shares of the company’s stock after selling 9,410 shares during the quarter. Rhumbline Advisers’ holdings in […] - 2025-06-20 04:22:49
GAMMA Investing LLC Raises Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA): GAMMA Investing LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1,961.2% during the first quarter, Holdings Channel.com reports. The firm owned 7,544 shares of the company’s stock after acquiring an additional 7,178 shares during the quarter. GAMMA Investing LLC’s holdings in Intellia Therapeutics were worth $540,000 at the end of […] - 2025-06-19 04:08:57
Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright: Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […] - 2025-06-18 02:22:53
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Brokerages: Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one […] - 2025-06-04 04:52:47
Nuveen Asset Management LLC Sells 105,170 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA): Nuveen Asset Management LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 28.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 260,697 shares of the company’s stock after selling 105,170 shares during the quarter. Nuveen Asset Management LLC’s […] - 2025-06-03 06:04:57
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC: UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 483,185 shares of the company’s […] - 2025-06-03 05:13:02
ProShare Advisors LLC Has $389,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA): ProShare Advisors LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 38.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,404 shares of the company’s stock after acquiring an additional 9,196 shares during the period. ProShare Advisors LLC’s holdings in Intellia Therapeutics were worth $389,000 at the end […] - 2025-05-29 05:04:57
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 15,888 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 227,255 shares of the company’s stock after buying an additional 15,888 shares during the period. MIRAE […] - 2025-05-21 05:40:53
BNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA): BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company’s stock after purchasing an additional 192,096 shares during […] - 2025-05-14 06:12:50
Guggenheim Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00: Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target cut by investment analysts at Guggenheim from $55.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 440.87% from the stock’s previous close. […] - 2025-05-14 02:56:48
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $36.47 Consensus Target Price from Brokerages: Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, thirteen have assigned a buy recommendation […] - 2025-05-13 02:44:49
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Cut by Voya Investment Management LLC: Voya Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,829 shares of the company’s stock after selling 2,213 shares during the period. Voya Investment Management LLC’s holdings in Intellia […] - 2025-05-12 05:26:58
Citigroup Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $10.00: Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […] - 2025-05-12 04:26:47
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Mariner LLC: Mariner LLC decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,820 shares of the company’s stock after selling 2,496 shares during the quarter. Mariner LLC’s holdings in Intellia Therapeutics were worth […] - 2025-05-08 04:38:44
Dimensional Fund Advisors LP Purchases 528,962 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA): Dimensional Fund Advisors LP increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 36.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,976,212 shares of the company’s stock after purchasing an additional 528,962 shares during the quarter. […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Buys 3,491 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA): MetLife Investment Management LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,187 shares of the company’s stock after purchasing an additional 3,491 shares during the period. […] - 2025-05-05 05:22:56
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought: Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again. Her most popular exchange-traded fund has risen 6% over the past month, a welcome contrast to the flat overall market in that time. Her 14% retur - 2025-04-30 11:15:00

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) NTLA holdings

Date	Number of NTLA Shares Held	Base Market Value of NTLA Shares	Local Market Value of NTLA Shares	Change in NTLA Shares Held	Change in NTLA Base Value	Current Price per NTLA Share Held	Previous Price per NTLA Share Held
2025-12-03 (Wednesday)	75,594	USD 684,882	USD 684,882	0	USD 72,571	USD 9.06001	USD 8.09999
2025-12-02 (Tuesday)	75,594	USD 612,311	USD 612,311	2,730	USD -1,204	USD 8.09999	USD 8.42
2025-12-01 (Monday)	72,864	USD 613,515	USD 613,515	0	USD -41,532	USD 8.42	USD 8.99
2025-11-28 (Friday)	72,864	USD 655,047	USD 655,047	182	USD 35,796	USD 8.99	USD 8.52001
2025-11-27 (Thursday)	72,682	USD 619,251	USD 619,251	0	USD 0	USD 8.52001	USD 8.52001
2025-11-26 (Wednesday)	72,682	USD 619,251	USD 619,251	546	USD 2,488	USD 8.52001	USD 8.55
2025-11-25 (Tuesday)	72,136	USD 616,763	USD 616,763	910	USD 22,026	USD 8.55	USD 8.35
2025-11-24 (Monday)	71,226	USD 594,737	USD 594,737	182	USD 11,466	USD 8.35	USD 8.21
2025-11-21 (Friday)	71,044	USD 583,271	USD 583,271	0	USD 12,077	USD 8.21	USD 8.04
2025-11-20 (Thursday)	71,044	USD 571,194	USD 571,194	-724	USD -20,174	USD 8.04	USD 8.24
2025-11-19 (Wednesday)	71,768	USD 591,368	USD 591,368	181	USD -14,974	USD 8.24	USD 8.47
2025-11-18 (Tuesday)	71,587	USD 606,342	USD 606,342	1,086	USD 8,494	USD 8.47	USD 8.47999
2025-11-17 (Monday)	70,501	USD 597,848	USD 597,848	362	USD -12,361	USD 8.47999	USD 8.7

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NTLA by Blackrock for IE00BDZVHG35

Show aggregate share trades of NTLA

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 2,730 8.490 8.085 8.125 USD 22,183 11.43
2025-11-28 BUY 182 9.100 8.530 8.587 USD 1,563 11.45
2025-11-26 BUY 546 8.630 8.400 8.423 USD 4,599 11.48
2025-11-26 BUY 546 8.630 8.400 8.423 USD 4,599 11.48
2025-11-25 BUY 910 8.610 8.185 8.228 USD 7,487 11.50
2025-11-24 BUY 182 8.370 8.135 8.159 USD 1,485 11.51
2025-11-20 SELL -724 8.040* 11.55 Profit of 8,361 on sale
2025-11-19 BUY 181 8.240* 11.57
2025-11-18 BUY 1,086 8.470* 11.58
2025-11-17 BUY 362 8.805 8.230 8.287 USD 3,000 11.60
2025-11-14 BUY 181 8.880 8.380 8.430 USD 1,526 11.61
2025-11-12 BUY 180 10.330 9.280 9.385 USD 1,689 11.64
2025-11-10 BUY 180 10.770 9.650 9.762 USD 1,757 11.66
2025-11-06 BUY 179 13.500 12.220 12.348 USD 2,210 11.67
2025-11-04 BUY 180 13.110 12.190 12.282 USD 2,211 11.65
2025-10-30 BUY 900 12.700 11.630 11.737 USD 10,563 11.64
2025-10-29 BUY 360 13.120 14.000 13.912 USD 5,008 11.63
2025-10-22 SELL -716 24.580 26.900 26.668 USD -19,094 11.36 Loss of -10,962 on sale
2025-10-20 BUY 358 27.980 28.250 28.223 USD 10,104 11.17
2025-10-17 BUY 894 24.750 25.180 25.137 USD 22,472 11.09
2025-10-15 BUY 1,424 25.930 26.319 26.280 USD 37,423 11.00
2025-10-03 BUY 1,260 19.960 20.980 20.878 USD 26,306 10.87
2025-10-02 BUY 180 20.440 20.585 20.570 USD 3,703 10.81
2025-09-30 BUY 360 17.270 17.530 17.504 USD 6,301 10.73
2025-09-26 BUY 360 16.310 16.619 16.588 USD 5,972 10.65
2025-09-25 BUY 360 16.610 17.470 17.384 USD 6,258 10.62
2025-09-17 BUY 543 12.410 13.100 13.031 USD 7,076 10.57
2025-07-17 SELL -358 11.830 12.400 12.343 USD -4,419 10.53 Loss of -650 on sale
2025-07-11 SELL -1,440 11.535 12.125 12.066 USD -17,375 10.50 Loss of -2,260 on sale
2025-07-02 BUY 9,900 10.730 11.080 11.045 USD 109,345 10.47
2025-06-25 BUY 360 9.560 9.660 9.650 USD 3,474 10.50
2025-06-20 BUY 2,763 9.200 9.943 9.869 USD 27,267 10.52
2025-06-11 BUY 344 8.370 8.688 8.656 USD 2,978 10.60
2025-06-10 BUY 346 8.470 9.125 9.060 USD 3,135 10.62
2025-06-04 SELL -173 7.670 7.840 7.823 USD -1,353 10.71 Profit of 499 on sale
2025-04-23 BUY 172 8.090 8.900 8.819 USD 1,517 11.41
2025-04-10 SELL -1,376 6.770 6.910 6.896 USD -9,489 11.81 Profit of 6,768 on sale
2025-04-08 SELL -172 6.280 7.030 6.955 USD -1,196 11.93 Profit of 856 on sale
2025-04-07 SELL -172 6.540 6.880 6.846 USD -1,178 12.00 Profit of 886 on sale
2025-04-04 SELL -865 6.630 6.910 6.882 USD -5,953 12.06 Profit of 4,477 on sale
2025-04-01 BUY 708 6.655 7.135 7.087 USD 5,018 12.18
2025-03-31 SELL -519 7.110 7.830 7.758 USD -4,026 12.24 Profit of 2,327 on sale
2025-03-21 BUY 3,042 9.000 9.075 9.067 USD 27,583 12.53
2025-03-14 SELL -2,624 9.140 9.600 9.554 USD -25,070 12.76 Profit of 8,420 on sale
2025-03-07 SELL -326 10.350 10.680 10.647 USD -3,471 13.00 Profit of 768 on sale
2025-03-04 SELL -163 9.095 9.530 9.486 USD -1,546 13.17 Profit of 601 on sale
2025-02-25 BUY 326 10.710 11.860 11.745 USD 3,829 13.41
2025-02-19 SELL -162 12.280 12.800 12.748 USD -2,065 13.51 Profit of 124 on sale
2025-02-13 BUY 486 9.640 9.715 9.708 USD 4,718 13.74
2025-02-12 BUY 162 9.510 9.580 9.573 USD 1,551 13.83
2025-02-11 BUY 648 9.210 9.476 9.449 USD 6,123 13.93
2024-12-30 SELL -5,493 11.410 11.850 11.806 USD -64,850 15.51 Profit of 20,349 on sale
2024-11-18 SELL -2,625 14.170 15.200 15.097 USD -39,630 16.51 Profit of 3,714 on sale
2024-11-08 SELL -175 16.730 16.995 16.969 USD -2,969 16.49 Loss of -84 on sale
2024-10-21 SELL -175 20.670 21.093 21.051 USD -3,684 0.00 Loss of -3,684 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	2,730	8.490	8.085	8.125	USD 22,183	11.43
2025-11-28	BUY	182	9.100	8.530	8.587	USD 1,563	11.45
2025-11-26	BUY	546	8.630	8.400	8.423	USD 4,599	11.48
2025-11-26	BUY	546	8.630	8.400	8.423	USD 4,599	11.48
2025-11-25	BUY	910	8.610	8.185	8.228	USD 7,487	11.50
2025-11-24	BUY	182	8.370	8.135	8.159	USD 1,485	11.51
2025-11-20	SELL	-724			8.040*		11.55 Profit of 8,361 on sale
2025-11-19	BUY	181			8.240*		11.57
2025-11-18	BUY	1,086			8.470*		11.58
2025-11-17	BUY	362	8.805	8.230	8.287	USD 3,000	11.60
2025-11-14	BUY	181	8.880	8.380	8.430	USD 1,526	11.61
2025-11-12	BUY	180	10.330	9.280	9.385	USD 1,689	11.64
2025-11-10	BUY	180	10.770	9.650	9.762	USD 1,757	11.66
2025-11-06	BUY	179	13.500	12.220	12.348	USD 2,210	11.67
2025-11-04	BUY	180	13.110	12.190	12.282	USD 2,211	11.65
2025-10-30	BUY	900	12.700	11.630	11.737	USD 10,563	11.64
2025-10-29	BUY	360	13.120	14.000	13.912	USD 5,008	11.63
2025-10-22	SELL	-716	24.580	26.900	26.668	USD -19,094	11.36 Loss of -10,962 on sale
2025-10-20	BUY	358	27.980	28.250	28.223	USD 10,104	11.17
2025-10-17	BUY	894	24.750	25.180	25.137	USD 22,472	11.09
2025-10-15	BUY	1,424	25.930	26.319	26.280	USD 37,423	11.00
2025-10-03	BUY	1,260	19.960	20.980	20.878	USD 26,306	10.87
2025-10-02	BUY	180	20.440	20.585	20.570	USD 3,703	10.81
2025-09-30	BUY	360	17.270	17.530	17.504	USD 6,301	10.73
2025-09-26	BUY	360	16.310	16.619	16.588	USD 5,972	10.65
2025-09-25	BUY	360	16.610	17.470	17.384	USD 6,258	10.62
2025-09-17	BUY	543	12.410	13.100	13.031	USD 7,076	10.57
2025-07-17	SELL	-358	11.830	12.400	12.343	USD -4,419	10.53 Loss of -650 on sale
2025-07-11	SELL	-1,440	11.535	12.125	12.066	USD -17,375	10.50 Loss of -2,260 on sale
2025-07-02	BUY	9,900	10.730	11.080	11.045	USD 109,345	10.47
2025-06-25	BUY	360	9.560	9.660	9.650	USD 3,474	10.50
2025-06-20	BUY	2,763	9.200	9.943	9.869	USD 27,267	10.52
2025-06-11	BUY	344	8.370	8.688	8.656	USD 2,978	10.60
2025-06-10	BUY	346	8.470	9.125	9.060	USD 3,135	10.62
2025-06-04	SELL	-173	7.670	7.840	7.823	USD -1,353	10.71 Profit of 499 on sale
2025-04-23	BUY	172	8.090	8.900	8.819	USD 1,517	11.41
2025-04-10	SELL	-1,376	6.770	6.910	6.896	USD -9,489	11.81 Profit of 6,768 on sale
2025-04-08	SELL	-172	6.280	7.030	6.955	USD -1,196	11.93 Profit of 856 on sale
2025-04-07	SELL	-172	6.540	6.880	6.846	USD -1,178	12.00 Profit of 886 on sale
2025-04-04	SELL	-865	6.630	6.910	6.882	USD -5,953	12.06 Profit of 4,477 on sale
2025-04-01	BUY	708	6.655	7.135	7.087	USD 5,018	12.18
2025-03-31	SELL	-519	7.110	7.830	7.758	USD -4,026	12.24 Profit of 2,327 on sale
2025-03-21	BUY	3,042	9.000	9.075	9.067	USD 27,583	12.53
2025-03-14	SELL	-2,624	9.140	9.600	9.554	USD -25,070	12.76 Profit of 8,420 on sale
2025-03-07	SELL	-326	10.350	10.680	10.647	USD -3,471	13.00 Profit of 768 on sale
2025-03-04	SELL	-163	9.095	9.530	9.486	USD -1,546	13.17 Profit of 601 on sale
2025-02-25	BUY	326	10.710	11.860	11.745	USD 3,829	13.41
2025-02-19	SELL	-162	12.280	12.800	12.748	USD -2,065	13.51 Profit of 124 on sale
2025-02-13	BUY	486	9.640	9.715	9.708	USD 4,718	13.74
2025-02-12	BUY	162	9.510	9.580	9.573	USD 1,551	13.83
2025-02-11	BUY	648	9.210	9.476	9.449	USD 6,123	13.93
2024-12-30	SELL	-5,493	11.410	11.850	11.806	USD -64,850	15.51 Profit of 20,349 on sale
2024-11-18	SELL	-2,625	14.170	15.200	15.097	USD -39,630	16.51 Profit of 3,714 on sale
2024-11-08	SELL	-175	16.730	16.995	16.969	USD -2,969	16.49 Loss of -84 on sale
2024-10-21	SELL	-175	20.670	21.093	21.051	USD -3,684	0.00 Loss of -3,684 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NTLA

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	2,488,216	25,912	4,783,026	52.0%
2025-09-18	3,275,170	25,808	8,092,762	40.5%
2025-09-17	1,795,760	5,805	3,049,648	58.9%
2025-09-16	882,780	1,110	3,448,059	25.6%
2025-09-15	742,270	87	1,788,362	41.5%
2025-09-12	722,335	400	1,382,221	52.3%
2025-09-11	875,864	7,054	1,871,681	46.8%
2025-09-10	1,504,239	5,762	2,264,600	66.4%
2025-09-09	1,403,874	13,341	2,383,475	58.9%
2025-09-08	918,117	138	1,520,959	60.4%
2025-09-05	1,009,137	2,144	2,403,556	42.0%
2025-09-04	673,355	7,237	1,306,221	51.5%
2025-09-03	1,086,350	1,583	2,619,353	41.5%
2025-09-02	670,397	1,167	1,423,047	47.1%
2025-08-29	537,468	2,100	1,149,466	46.8%
2025-08-28	861,127	0	1,850,840	46.5%
2025-08-27	562,885	3	1,151,551	48.9%
2025-08-26	587,471	218	1,339,282	43.9%
2025-08-25	944,676	2,534	2,848,396	33.2%
2025-08-22	471,994	1,010	1,271,512	37.1%
2025-08-21	664,420	0	1,098,368	60.5%
2025-08-20	717,661	175	1,330,497	53.9%
2025-08-19	1,307,361	3,209	1,995,173	65.5%
2025-08-18	749,693	4,852	1,667,250	45.0%
2025-08-15	929,774	629	2,294,404	40.5%
2025-08-14	1,573,720	948	2,631,090	59.8%
2025-08-13	1,587,305	1,257	2,999,673	52.9%
2025-08-12	943,033	2,912	1,526,981	61.8%
2025-08-11	673,892	596	1,352,233	49.8%
2025-08-08	1,135,026	5,919	1,684,235	67.4%
2025-08-07	930,537	305	1,823,817	51.0%
2025-08-06	841,940	455	1,751,626	48.1%
2025-08-05	766,498	153	1,479,649	51.8%
2025-08-04	806,213	981	1,511,507	53.3%
2025-08-01	1,211,552	2,121	2,016,622	60.1%
2025-07-31	1,494,603	6,236	2,951,398	50.6%
2025-07-30	876,601	1,300	1,994,394	44.0%
2025-07-29	903,380	2,893	2,182,944	41.4%
2025-07-28	602,154	1,713	1,783,814	33.8%
2025-07-25	830,629	114,157	2,043,998	40.6%
2025-07-24	1,624,048	106,013	3,581,477	45.3%
2025-07-23	1,590,065	13,570	3,054,683	52.1%
2025-07-22	899,460	3,299	1,834,330	49.0%
2025-07-21	1,344,537	6,371	2,694,803	49.9%
2025-07-18	725,129	632	1,386,254	52.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE